Survivors of childhood, adolescent, and young adult cancer, previously treated with
anthracycline chemotherapy (including mitoxantrone) or radiotherapy in which the heart was …

Survivors of childhood cancer treated with anthracycline chemotherapy or chest radiation
are at an increased risk of developing congestive heart failure. In this population, congestive …

1928 Circulation October 22, 2013 mental health, functional status, activity limitations,
cancerrelated pain, and cancer-related anxiety) declined moderately to severely in 44%. 5 …

The multidrug resistance protein 1 (MRP1) encoded by ABCC1 was originally discovered as
a cause of multidrug resistance in tumor cells. However, it is now clear that MRP1 serves a …

Background: Multiple pharmacogenomic studies have identified the synonymous genomic
variant rs7853758 (G> A, L461L) and the intronic variant rs885004 in SLC28A3 (solute …

High-grade osteosarcomas are the most common primary malignant tumors of bone. With
complete surgical resection and multi-agent chemotherapy up to 70% of patients with high …

Anthracyclines are used in over 50% of childhood cancer treatment protocols, but their
clinical usefulness is limited by anthracycline-induced cardiotoxicity (ACT) manifesting as …

The management of individual patients requiring anthracyclines remains challenging
because uncertainty persists on predictors of cardiotoxicity. We aimed to perform a …

Anthracyclines are ranked among the most effective chemotherapeutics against cancer.
They are glycoside drugs comprising the amino sugar daunosamine linked to a hydroxy …

Aims Anthracycline‐induced cardiotoxicity (ACT) occurs in 57% of treated patients and
remains an important limitation of anthracycline‐based chemotherapy. In various genetic …